Approximately one‐half of individuals with cancer face personal economic burdens
associated with the disease and its treatment, a problem known as financial toxicity (FT). FT …

Because genetic alterations including mutations, overexpression, translocations, and
dysregulation of protein kinases are involved in the pathogenesis of many illnesses, this …

Clinical trials are time consuming, expensive, and often burdensome on patients. Clinical
trials can fail for many reasons. This survey reviews many of these reasons and offers …

Because mutations, overexpression, and dysregulation of protein kinases play essential
roles in the pathogenesis of many illnesses, this enzyme family has become one of the most …

Abstract “Financial toxicity” has now become a familiar term used in the discussion of cancer
drugs, and it is gaining traction in the literature given the high price of newer classes of …

Background: With rising cancer care costs, including high-priced cancer drugs, financial
hardship is increasingly documented among cancer survivors in the United States; research …

Background: Patients with cancer experience financial toxicity from the costs of treatment, as
well as material and psychologic stress related to this burden. A synthesized understanding …

BACKGROUND Cancer and its treatment lead to increased financial distress for patients. To
the authors' knowledge, to date, no standardized patient‐reported outcome measure has …

Background Aromatase inhibitors are a standard of care for hormone receptor-positive
locally advanced or metastatic breast cancer. We investigated whether the selective …

Purpose Patients with cancer are more likely to file for bankruptcy than the general
population, but the impact of severe financial distress on health outcomes among patients …